Threshold Pharmaceuticals (THLD +7.2% to $4.78) receives an upgrade to Overweight from Neutral...

|About: Threshold Pharmaceuticals... (THLD)|By:, SA News Editor

Threshold Pharmaceuticals (THLD +7.2% to $4.78) receives an upgrade to Overweight from Neutral from Piper Jaffray, which is impressed with the differentiation of Threshold's TH-302 drug for soft-tissue sarcoma compared with a rival product. Piper also believes that Threshold's hypoxia-activation platform will be able to be used to treat a wide range of cancers. Piper doubled the company's price target to $10.